Terms: = Thyroid cancer AND uPA AND Prognosis
12 results:
1. MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival.
Molière S; Lodi M; Leblanc S; Gressel A; Mathelin C; Alpy F; Chenard MP; Tomasetto C
BMC Cancer; 2024 Mar; 24(1):295. PubMed ID: 38438841
[TBL] [Abstract] [Full Text] [Related]
2. In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic thyroid cancer Cell Lines.
Baldini E; Presutti D; Favoriti P; Santini S; Papoff G; Tuccilli C; Carletti R; Di Gioia C; Lori E; Ferent IC; Gagliardi F; Catania A; Pironi D; Tripodi D; D'Andrea V; Sorrenti S; Ruberti G; Ulisse S
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409084
[TBL] [Abstract] [Full Text] [Related]
3. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
Horvatic Herceg G; Herceg D; Kralik M; Kulic A; Bence-Zigman Z; Tomic-Brzac H; Bracic I; Kusacic-Kuna S; Prgomet D
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563
[TBL] [Abstract] [Full Text] [Related]
4. The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Baldini E; Sorrenti S; D'Armiento E; Di Matteo FM; Catania A; Ulisse S
G Chir; 2012 Oct; 33(10):305-10. PubMed ID: 23095556
[TBL] [Abstract] [Full Text] [Related]
5. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract] [Full Text] [Related]
6. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract] [Full Text] [Related]
7. Inhibitory effects of retinoic acid on invasiveness of human thyroid carcinoma cell lines in vitro.
Lan L; Cui D; Luo Y; Shi BY; Deng LL; Zhang GY; Wang H
J Endocrinol Invest; 2009 Oct; 32(9):731-8. PubMed ID: 19509478
[TBL] [Abstract] [Full Text] [Related]
8. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
Horvatić Herceg G; Herceg D; Kralik M; Bence-Zigman Z; Tomić-Brzac H; Kulić A
Wien Klin Wochenschr; 2006 Oct; 118(19-20):601-9. PubMed ID: 17136335
[TBL] [Abstract] [Full Text] [Related]
9. Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma.
Ivanova R; Soares P; Castro P; Sobrinho-Simões M
Virchows Arch; 2002 Apr; 440(4):418-24. PubMed ID: 11956824
[TBL] [Abstract] [Full Text] [Related]
10. Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines.
Havekes B; Schröder van der Elst JP; van der Pluijm G; Goslings BM; Romijn JA; Smit JW
J Endocrinol; 2000 Nov; 167(2):229-38. PubMed ID: 11054636
[TBL] [Abstract] [Full Text] [Related]
11. Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Ito Y; Takeda T; Kobayashi T; Wakasugi E; Tamaki Y; Umeshita K; Monden T; Shimano T; Monden M
Anticancer Res; 1996; 16(1):81-9. PubMed ID: 8615674
[TBL] [Abstract] [Full Text] [Related]
12. Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy.
Mira-y-Lopez R; Osborne MP; DePalo AJ; Ossowski L
Int J Cancer; 1991 Apr; 47(6):827-32. PubMed ID: 1901298
[TBL] [Abstract] [Full Text] [Related]
